[Ip-health] USA Today: Lobbyists battle over drug sales

[Thiru Balasubramaniam]

http://www.usatoday.com/money/industries/health/drugs/2009-07-28-insidebiol=
ogics_N.htm

Lobbyists battle over drug sales

By Fredreka Schouten, USA TODAY

WASHINGTON =97 As Congress struggles with a massive health care
overhaul, several lobbying powerhouses =97 including the pharmaceutical
industry and the nation's largest advocacy group for retirees =97 are
locked in a contentious fight over the future of biotechnology drugs.

Both sides have spent heavily to sway lawmakers in the debate over how
long to keep the expensive drugs exempt from generic competition.
President Obama is pushing for seven years of exclusivity as he looks
to trim costs to help pay for his health care plan =97 five years less
than what the industry wants.

PHARMACEUTICALS: Industry donates to drug plan foes

"If you extend that 12 years, obviously it's better for (drugmakers')
bottom line," Obama said Friday. "But it also means you're keeping
important drugs off the market and driving up those costs further."

The pharmaceutical industry counters that a longer period of
exclusivity is needed to recover its investments in "biologic drugs,"
which are made from living organisms and used to treat cancer,
multiple sclerosis and other serious diseases.

"We understand that it's important to save money in our health care
system, but it's also important to save lives," said Ken Johnson,
senior vice president of the Pharmaceutical Research and Manufacturers
of America. He said the group has spent "several million" on ads
promoting longer exclusivity rights.

He said a shorter period of market exclusivity "will chase off
investors and drive research and development overseas." Johnson noted
that drug companies have agreed to shoulder $80 billion of the health
plan's cost in part by lowering prices of drugs for seniors purchased
through Medicare.

The Biotechnology Industry Organization, which also backs at least 12
years of exclusivity, recently spent $300,000 on advertising.

On the other side, the AARP spent nearly $90,000 in May and July to
press its case in advertisements targeting selected lawmakers,
spokesman James Dau said. The AARP is part of a broad coalition that
includes generic-drug makers, consumer groups and labor unions.

The newspaper and airwave battles represent just a slice of the
spending.

A report out Tuesday from the watchdog group Common Cause found that
large drug companies and their associations have spent $238 million to
lobby Congress and federal agencies since 2007.

Records show that the groups backing greater competition from generic
copies also lobby heavily. The AARP, which represents 40 million older
Americans, spent nearly $57 million on lobbying during the same
period, according to data compiled by the non-partisan Center for
Responsive Politics.

This month, a Senate committee approved 12 years of exclusivity.
Attention shifts to the House, where a companion, 12-year bill
sponsored by Rep. Anna Eshoo, D-Calif., has 139 co-sponsors =97 compared
with 14 lawmakers who back a competing measure that would allow
generic competition after five years. Eshoo said she is working to
incorporate her plan into the larger health care bill the House Energy
and Commerce panel will consider when Congress returns in September.

Opponents of the 12-year period, such as Sen. Sherrod Brown, D-Ohio,
said they plan to wage a fight on the Senate floor to remove the
provision from the health care package.

Mark Merritt, who heads the Pharmaceutical Care Management
Association, said the battle is a test of "Washington's real capacity
for change." His association, which represents companies that manage
drug benefit programs for employers, supports five years of exclusivity.

"If Washington is unable to get real reform in biologics, it's a
terrible bellwether for health care reform," Merritt said.

------------------------------------------------------------


Thiru Balasubramaniam
Geneva Representative
Knowledge Ecology International (KEI)
thiru@keionline.org


Tel: +41 22 791 6727
Mobile: +41 76 508 0997